PSMA specific antibodies and their diagnostic and therapeutic use

Bibliography

• ISRAELI RS, POWELL CT, FAIR WR et al.: Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res. (1993) 3:227–230.
   Google Scholar
• HOLMES EH, GREENE TG, TINO WT et al.: Analysis of glycosylation of prostate specific membrane antigen derived from LISICaP cells, prostatic carcinoma tumors and serum from prostate cancer patients. Prostate (1996) 7 (Supp0:25–29.
   Google Scholar
• HOROSZEWICZ JS, KAWINSKI E, MURPHY GP: Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res. (1987) 7:927–936.
   PubMed Web of Science ®Google Scholar
• KAWAKAMI M, NAKAYAMA J: Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situhybridization. Cancer Res. (1997) 57:2321–2324.
   PubMed Web of Science ®Google Scholar
• TROYER JK, BECKETT ML, WRIGHT GL JR: Detection andcharacterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int. J. Cancer (1995) 62:552–558.
   PubMed Web of Science ®Google Scholar
• LOPES AD, DAVIS WL, ROSENSTRAUS MJ et al: Immuno-histochemical and Pharmacokinetic Characterization of the Site-specific Immunoconjugate CYT-356 Derived from Antiprostate Monoclonal Antibody 7E11-05. Cancer Res. (1990) 50:6423–6429.
   PubMed Web of Science ®Google Scholar
• ROSENSTROUS MJ, DAVIS WL, LOPES AD et al.: In vitro and in vivo reactivity of anti-prostate monoclonal antibody immunoconjugate 7E11.C5.3-GYK-DTPA. Antibody Immunoconj. Radiopharm. (1990) 3:54.
   Google Scholar
• SILVER DA, PELLICER I, FAIR WR et al.: Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin. Cancer Res. (1997) 3:81–85.
   PubMed Web of Science ®Google Scholar
• WRIGHT GL JR, GROB M, HALEY C et al.: Upregulation of prostate-specific antigen after androgen deprivation therapy. Urology (1996) 48:326–334.
   PubMed Web of Science ®Google Scholar
• SOKOLOFF RL, NORTON KC, GASIOR CL, MARKER KM, GRAUER LS: A dual-monoclonal sandwich assay for prostate-specific membrane antigen: Levels in tissues, seminal fluid and urine. Prostate (2000) 43:150–157.
   PubMed Web of Science ®Google Scholar
• ISRAELI RS, POWELL CT, CORR JG et al.: Expression of the prostate-specific membrane antigen. Cancer Res. (1994) 54:1807–1811.
   PubMed Web of Science ®Google Scholar
• CHANG SS, REUTER VE, HESTON WDW, GRAUER LS, GAUDIN PS: Short term neoadjuvant androgen deprivation therapy does not affect prostate specific membrane antigen expression in prostate tissues. Cancer (2000) 88:407–415.
   PubMed Web of Science ®Google Scholar
• BOSTWICK DG, PACELLI A, BLUTE M et al.: Prostatespecific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: study of 184 cases. Cancer (1998) 82:2256–2261.
   PubMed Web of Science ®Google Scholar
• SWEAT SD, PACELLI A, MURPHY GP, BOSTWICK DG: Prostate specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology (1998) 52:637–640.
   PubMed Web of Science ®Google Scholar
• CHANG SS, REUTER VE, HESTON WDW, BANDER NH,GRAUER LS, GAUDIN PB: Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. (1999) 59:3192–3198.
   PubMed Web of Science ®Google Scholar
• CHANG SS, O'KEEFE DS, BACIC DJ, REUTER VE, HESTONWDW, GAUDIN PB: Prostate-specific membrane antigen is produced in tumor-associated neovascula-ture. Clin. Cancer Res. (1999) 5:2674–2681.
   PubMed Web of Science ®Google Scholar
• TROYER JK, FENG Q, BECKETT ML et al.: Biochemicalcharacterization and mapping of the 7e11-05.3 epitope of the prostate-specific membrane antigen. Urology. Oncol (1995) 1:29–37.
   Google Scholar
• HOPP TP, WOODS KR: Prediction of protein antigenicdeterminants from amino acid sequences. Proc. Natl. Acad. Sci. USA (1981) 78:3824–3828.
   PubMed Web of Science ®Google Scholar
• MURPHY GP, TINO WT, HOLMES EH et al.: Measurementof prostate-specific membrane antigen in the serum with a new antibody. Prostate (1996) 28:266–271.
   PubMed Web of Science ®Google Scholar
• •First report of a monoclonal antibody specific for the extracellular domain of PSMA.
   Google Scholar
• ZHU ZY, ZHONG CP, XU WF et al.: PSMA mimotopeisolated from phage displayed peptide library can induce PSMA specific immune response. Cell Res. (1999) 9:271–280.
   PubMed Web of Science ®Google Scholar
• LIU H, MOY P, KIM S et al.: Monoclonal antibodies to theextracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res. (1997) 57:3629–3634.
   PubMed Web of Science ®Google Scholar
• •Description of PSMA extracellular domain-specific antibodies recognising linear sequence epitopes.
   Google Scholar
• LIU H, RAJASEKARAN AK, MOY P et al.: Constitutive andantibody-induced internalization of prostate-specific membrane antigen. Cancer Res. (1998) 58:4055–4060.
   PubMed Web of Science ®Google Scholar
• SMITH-JONES PM, VALLABAHAJOSULA S, GOLDSMITH SJet al.: In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res. (2000) 60:5237–5243.
   Google Scholar
• •Description of antibody binding properties to prostatic cancer cells.
   Google Scholar
• RICHSTONE L, YAO D, KIM S, LIU H, CHART RJ, BANDERNH: Eradication of prostate cancer xenografts by immunoconjugates targeting the extracellular domain of prostate-specific membrane antigen (PSMA). Proc. Amer. Soc. Clin. Oncol. (2000) 19:338a.
   Google Scholar
• SMITH-JONES PM, VALLABHAJOSULA S, NAVARRO V, GOLDSMITH SJ, BANDER NH: 90Y-huJ591 Mab specific to PSMA: Radioimmunotherapy (R11) studies in nude mice with prostate cancer LISICaP tumor. Eur. J. Nucl. Med. (2000) 27:S951.
   Google Scholar
• MCDEVITT MR, BARENDSWAARD E, MA D et al.: Ana-particle emitting antibody ([213BilI591) for radioim-munotherapy of prostate cancer. Cancer Res. (2000) 60:6095–6100.
   PubMed Web of Science ®Google Scholar
• MURPHY GP, GREENE TG, TINO WT, BOYNTON AL, HOLMES EH: Isolation and characterization of monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. J. Ural. (1998) 160:2396–2401.
   PubMed Web of Science ®Google Scholar
• •Description of PSMA extracellular domain-specific antibodies recognising linear sequence epitopes.
   Google Scholar
• TINO WT, HUBER MJ, LAKE TP, GREENE TG, MURPHY GP, HOLMES EH: Isolation and characterization of monoclonal antibodies specific for protein conforma-tional epitopes present in prostate-specific membrane antigen (PSMA). Hybridoma (2000) 19:249–257.
   PubMed Web of Science ®Google Scholar
• •Description of PSMA extracellular domain-specific antibodies recognising protein conformational epitopes.
   Google Scholar
• OLSON W: Development of vaccine and antibody therapies targeting prostate-specific membrane antigen. 7th Annual CaP CURE Scientific Retreat (2000) Lake Tahoe, NV, USA. www.capcure.org
   Google Scholar
• WOLCHOK JD: Xenogeneic genetic immunization with prostate-specific membrane antigen cDNAs. 7th Annual CaP CURE Scientific Retreat (2000) Lake Tahoe, NV, USA. www.capcure.org:34
   Google Scholar
• HOLMES EH, HUDSON D, TINO WT, HUBER MJ, LAKE TP:Development of human monoclonal antibodies specific for extracellular epitopes in prostate-specific membrane antigen (PSMA). 12th Intl. Con! Monoclonal Antibodies for Cancer (1999) San Diego, CA, USA.
   Google Scholar
• •Description of fully human monoclonal antibodies specific for protein conformational epitopes of PSMA.
   Google Scholar
• VARKARAKIS MJ, MURPHY GP, NELSON CMK, CHEHVAL M, MOORE RH, FLOCKS RH: Lymph node involvement in prostatic carcinoma. Um/ Clin. North Amer. (1975) 2:197–212.
   PubMedGoogle Scholar
• KRAMER S, GORICH J, GOTTFRIED HW et al.: Sensitivityof computed tomography in detecting local recurrence of prostatic carcinoma following radical prostatectomy. Br. J. Radial. (1997) 70:995–999.
   PubMed Web of Science ®Google Scholar
• SANFORD E, GRZONKA R, HEAL A et al.: Prostate cancer imaging with a new monoclonal antibody :a prelimi-nary report. Annals Surg. Oncol (1994) 1:400–404.
   PubMed Web of Science ®Google Scholar
• MURPHY GP: Radioscintiscanning of prostate cancer. Cancer (1995) 75:1819–1822.
   Web of Science ®Google Scholar
• KAHN D, WILLIAMS RD, MANYAK MJ et al.: Indium-111capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. j Ural. (1998) 159:2041–2047.
   PubMed Web of Science ®Google Scholar
• KAHN D, WILLIAMS RD, SELDIN DW et al.: Radioimmu- iii noscintigraphy withindium-labeled CYT-356 for the detection of occult prostate cancer recurrence. J. Ural. (1994) 152:1490–1495.
   PubMedGoogle Scholar
• BABAIAN RJ, SAYER J, PODOLOFF DA et al.: Radioimmu-noscintigraphy of pelvic lymph nodes with 111Indium-labeled monoclonal antibody CYT-356. J. Ural. (1994) 152:1952–1955.
   PubMedGoogle Scholar
• HASEMAN MK, REED NL, ROSENTHAL SA: Monoclonalantibody imaging of occult prostate cancer in patients with elevated prostate-specific antigen: Positron emission tomography and biopsy correlation. Clin. Nucl. Med. (1996) 21:703–713.
   Google Scholar
• ULCHAKER J, KLEIN E, ZIPPE C et al.: Indium-111capromab monoclonal antibody: Utility in differenti-ating local versus distant relapse after radical prostatectomy. j Ural. (1997) 157 (Abst):205 .
   Google Scholar
• BURGERS JK, HINKLE GH, HASEMAN MK: Monoclonalantibody imaging of recurrent and metastatic prostate cancer. Semin. Ural. (1995) 13:103–112.
   PubMedGoogle Scholar
• KAHN D, WILLIAMS RD, HASEMAN MK, REED NL, MILLERSJ, GERSTBREIN J: Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy. j Clin. Oncol. (1998) 16:284–289.
   PubMed Web of Science ®Google Scholar
• POLASCIK TJ, GURGANUS RT, PARTIN AW et al.:Comparison of staging algorithms and a monoclonal antibody scan (ProstaScint) to predict lymph node involvement in high-risk prostate cancer. J Ural. (1998) 159:289.
   Web of Science ®Google Scholar
• CHENGAZI VU, FENELEY MR, ELLISON D et al.: Imagingprostate cancer with technetium-99m-7E11.C5.3 (CYT-351). J. Nucl. Med. (1997) 38:675–682.
   Google Scholar
• HINKLE GH, BURGERS JK, NEAL CE et al.: Multicenterradioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide. Cancer (1998) 83:739–747.
   PubMed Web of Science ®Google Scholar
• ELGAMAL AA, TROYCHAK MJ, MURPHY GP: ProstaScintmay enhance identification of prostate cancer recurrence after prostatectomy, radiation, or hormone therapy: Analysis of 136 scans of 100 patients. Prostate (1998) 37:261–269.
   PubMed Web of Science ®Google Scholar
• MANYAK MJ, HINKLE GH, OLSEN JO et al.: Immunoscin-tigraphy with indium-111-capromab pendetide: Evaluation before definitive therapy in patients with prostate cancer. Urology (1999) 54:1058–1063.
   PubMed Web of Science ®Google Scholar
• MURPHY GP, MAGUIRE RT, ROGERS B etal.: Comparison of serum PSMA, PSA levels with results of cytogen-356 ProstaScint scanning in prostatic cancer patients. Prostate (1997) 33:281–285.
   Google Scholar
• FIGG WD, AMMERMAN BA, PATRONAS N et al.: Lack of correlation between prostate-specific antigen and the presence of measurable soft tissue metastases in hormone-refractory prostate cancer. Cancer Invest. (1996) 14:513–517.
   PubMed Web of Science ®Google Scholar
• MURPHY GP, TROYCHAK MJ, COBB OE et al.: Evaluation of PSA, free PSA, PSMA and total and bone alkaline phosphatase levels compared to bone scans in the management of patients with metastatic prostate cancer. Prostate (1997) 33:141–146.
   PubMed Web of Science ®Google Scholar
• DEB N, GORIS M, TRISLER K et al.: Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody. Clin. Cancer Res. (1996) 2:1289–1297.
   PubMed Web of Science ®Google Scholar
• HAMILTON A, KINGS, LIU H, MOY P, BANDER N, CARR F: A novel humanised antibody against prostate-specific membrane antigen (PSMA) for in vivo targeting and therapy. Proc. Amer. Assoc. Cancer Res. (1998) 39:440.
   Google Scholar
• BANDER NH, NANUS D, BREMER S et al.: Phase I clinical trial targeting a monoclonal antibody (mab) to the extracellular domain of prostate specific membrane antigen (PSMA) in patients with hormone-independent prostate cancer. Proc. Amer. Soc. Clin. Oncol. (2000) 19:477a.
   Google Scholar
• BANDER NH: Monoclonal antibody therapy for prostate cancer. 7th Annual CaP CURE Scientific Retreat, Lake Tahoe, NV. (2000) www.capcure.org
   Google Scholar
• •Results of a Phase I clinical trial with a PSMA-specific linear sequence epitope antibody.
   Google Scholar
• SALGALLER ML, THURNHER M, BARTSCH G, BOYNTON AL, MURPHY GP: Report from the International Union Against Cancer (UICC) Tumor Biology Committee: UICC workshop on the use of dendritic cells in cancer clinical trials. Cancer (1999) 6:2674–2683.
   Google Scholar
• MURPHY GP, TJOA BA, SIMMONS SJ et al.: Phase II prostate cancer vaccine trial: Report of a study involving 37 patients with disease recurrence following primary treatment. Prostate (1999) 39:54–59.
   PubMed Web of Science ®Google Scholar